Quantifying the risk of incompatible kidney transplantation: A multicenter study

American Journal of Transplantation

Volumn 14, Issue 7, 2014, Pages 1573-1580

  Orandi, B J ^a   Garonzik Wang, J M ^a   Massie, A B ^a   Zachary, A A ^a   Montgomery, J R ^a   Van Arendonk, K J ^a   Stegall, M D ^b   Jordan, S C ^c   Oberholzer, J ^d   Dunn, T B ^e   Ratner, L E ^f   Kapur, S ^g   Pelletier, R P ^h   Roberts, J P ⁱ   Melcher, M L ^j   Singh, P ^k   Sudan, D L ^l   Posner, M P ^m   El Amm, J M ⁿ   Shapiro, R ^o   Cooper, M ^p   Lipkowitz, G S ^q   Rees, M A ^r   Marsh, C L ^s   Sankari, B R ^t   Gerber, D A ^u   Nelson, P W ^v   Wellen, J ^w   Bozorgzadeh, A ^x   Gaber, A O ^y   Montgomery, R A ^a   Segev, D L ^a   more..

^a JOHNS HOPKINS HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g WEILL CORNELL MEDICAL CENTER   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j STANFORD UNIVERSITY   (United States)

^k THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

^m VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ INTEGRIS BAPTIST MEDICAL CENTER   (United States)

^o UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^p GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^q BAYSTATE MEDICAL CENTER   (United States)

^r UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^s SCRIPPS CLINIC   (United States)

^t SAINT VINCENT HOSPITAL   (United States)

^u UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^v ST VINCENT HOSPITAL   (United States)

^w BARNES JEWISH HOSPITAL   (United States)

^x UMASS MEMORIAL MEDICAL CENTER   (United States)

^y HOUSTON METHODIST HOSPITAL   (United States)

more..

Author keywords

Alloantibody; clinical research; graft survival; health services and outcomes research; kidney transplantation; law; legislation; living donor; nephrology; practice; Scientific Registry for Transplant Recipients (SRTR); simulation

Indexed keywords

HLA ANTIBODY; HUMAN LYMPHOCYTE ANTIGEN DONOR SPECIFIC ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; HLA ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; INCOMPATIBLE LIVE DONOR KIDNEY TRANSPLANTATION; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MORTALITY; POSITIVE CYTOTOXIC CROSSMATCH; POSITIVE FLOW NEGATIVE CYTOTOXIC CROSSMATCH; POSITIVE LUMINEX NEGATIVE FLOW CROSSMATCH; PRIORITY JOURNAL; RISK ASSESSMENT; BLOOD GROUP INCOMPATIBILITY; CLINICAL PRACTICE; CLINICAL TRIAL; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; INCIDENCE; KIDNEY FAILURE, CHRONIC; LEGISLATION AND JURISPRUDENCE; MIDDLE AGED; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; SURVIVAL RATE;

ADULT; ANTIBODIES; BLOOD GROUP INCOMPATIBILITY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84903137440     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12786     Document Type: Article

References (37)

1. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
2. Garonzik-Wang JM, Montgomery RA, Kucirka LM, Berger JC, Warren DS, Segev DL., Incompatible live-donor kidney transplantation in the United States: Results of a national survey. Clin J Am Soc Nephrol 2011; 6: 2041-2046.
3. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13: 76-85.
4. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582-589.
5. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: Longer-term outcomes. Am J Transplant 2009; 9: 536-542.
6. SRTR Risk Model Documentation: Kidney, Living Donor, Adult, First-Year Graft Survival. June 26, 2013; Available at: http://www.srtr.org/csr/current/ Centers/201206/modtabs/Risk/KIADL2G.pdf. Accessed June 26, 2013.
7. Ellis TM., Interpretation of HLA single antigen bead assays. Transplant Rev (Orlando) 2013; 27: 108-111.
8. Zachary AA, Vega RM, Lucas DP, Leffell MS., HLA antibody detection and characterization by solid phase immunoassays: Methods and pitfalls. Methods Mol Biol 2012; 882: 289-308.
9. Dickinson DM, Dykstra DM, Levine GN, Li S, Welch JC, Webb RL., AT transplant data: Sources collection and research considerations, 2004. Am J Transplant 2005; 5 (4 Pt 2): 850-861.
10. Massie AB, Segev DL., Rates of false flagging due to statistical artifact in CMS evaluations of transplant programs: Results of a stochastic simulation. Am J Transplant 2013; 13: 2044-2051.
11. Akalin E, Ames S, Sehgal V, et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 2003; 76: 1444-1447.
12. Akalin E, Bromberg JS., Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 2005; 66: 359-363.
13. Al Meshari K, Pall A, Chaballout A, et al. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: A single-center experience in more than 100 patients. Transplant Proc 2013; 45: 1423-1426.
14. Bachler K, Amico P, Honger G, et al. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010; 10: 1254-1262.
15. Blumberg JM, Gritsch HA, Reed EF, et al. Kidney paired donation in the presence of donor-specific antibodies. Kidney Int 2013; 84: 1009-1016.
16. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3: 1017-1023.
17. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758-760.
18. Higgins R, Lowe D, Hathaway M, et al. Human leukocyte antigen antibody-incompatible renal transplantation: Excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 2011; 92: 900-906.
19. Klein K, Susal C, Schafer SM, et al. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Atheroscler Suppl 2013; 14: 199-202.
20. Magee CC, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S., Renal transplantation in patients with positive lymphocytotoxicity crossmatches: One center's experience. Transplantation 2008; 86: 96-103.
21. Mai ML, Ahsan N, Wadei HM, et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009; 87: 227-232.
22. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
23. Morath C, Beimler J, Opelz G, et al. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012; 25: 506-517.
24. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70: 1531-1536.
25. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S., A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346-351.
26. Thielke, JJ, West-Thielke PM, Herren HL, et al. Living donor kidney transplantation across positive crossmatch: The University of Illinois at Chicago experience. Transplantation 2009; 87: 268-273.
27. Tyan DB, Li VA, Czer L, Trento A, Jordan SC., Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553-562.
28. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251.
29. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684-2694.
30. Montgomery RA, Lonze BE, Jackson AM., Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients. Curr Opin Organ Transplant 2011; 16: 439-443.
31. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132-2143.
32. Gibney EM, Cagle LR, Freed B, Warnell SE, Chan L, Wiseman AC., Detection of donor-specific antibodies using HLA-coated microspheres: Another tool for kidney transplant risk stratification. Nephrol Dial Transplant 2006; 21: 2625-2629.
33. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
34. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.
35. Zachary AA, Lucas DP, Detrick B, Leffell MS., Naturally occurring interference in Luminex assays for HLA-specific antibodies: Characteristics and resolution. Hum Immunol 2009; 70: 496-501.
36. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant 2013; 13: 1859-1870.
37. Zachary AA, Klingman L, Thorne N, et al. Variations of the lymphocytotoxicity test. An evaluation of sensitivity and specificity. Transplantation 1995; 60: 498-503. Diseases Diseases